[Standardization of next-generation sequencing for detecting mutations associated with targeted therapy and immunotherapy based on dynamic pattern ofexpandabledetectionrange].

Next-generation sequencing (NGS) has laid the foundation for precision oncology care. NGS technologynot only represents an innovation in the methodology but also brings about a revolution in the concept of detecting gene alterations for targeted therapy and immunotherapy of cancers. As basic biomedical research and drug development progress, the landscape of biomarkers associated with gene alterations continues to evolve. Thus, the standardization of NGS-based gene alterations detection should take into account the characteristics of NGS methods and the gene alteration biomarkers. To be specific, whether employed as in vitro diagnostic products or laboratory-developed tests, the detection range can be expanded in response to changes in the clinical evidence level of biomarkers during the process of assay development and clinical application. Such adjustment needs the analytical validation results for supplemented genes or mutant sites within a predefined detection system, which will maximally fulfill the evolving clinical demands in cancer diagnosis and treatment, simultaneously mitigate potential risks effectively. This article primarily discusses the standardization pathway for NGS testing of gene alterations in cancer by focusing on the characteristics of NGS methods, gene alteration biomarkers, and the current status of the standardization of NGS application.高通量测序（NGS）是精准肿瘤学的关键技术支撑。肿瘤靶向和免疫治疗基因突变NGS不仅是方法原理的创新，同时也有检测理念的变革；肿瘤基因突变标志物并非固定不变，其随着基础研究和药物研发进展而不断更新。肿瘤基因突变NGS检测的规范化应结合NGS方法和肿瘤治疗基因突变标志物的特点来进行。肿瘤治疗基因突变NGS检测，无论是体外诊断产品，还是自建方法，在方法研发和临床应用过程中，在一个确定的检测系统下，根据标志物临床证据等级的变化，在增加补充新位点分析性能确认结果的基础上，进行检测范围动态扩展，是实现最大程度满足肿瘤临床诊疗需求且有效控制风险的规范化路径。本文主要结合肿瘤靶向和免疫治疗基因突变NGS检测方法的特点、肿瘤基因突变标志物的特点以及目前肿瘤基因突变NGS检测规范化应用的现状进行论述，探讨我国肿瘤基因突变NGS检测的规范化路径。.